Retatrutide · 10 mg
Document reference: ELX-COA-01
Laboratory: FREEDOM
COA issued: July 18, 2026
Quality & Testing
Transparency at the Batch Level
Product identification, batch references and available laboratory reports should be reviewed together. Published studies are separate from batch-specific testing.
EULIX VERIFY™
Look up an EULIX document reference from the COA library.
Document references identify these published copies; they are not EULIX inventory lot numbers.
Laboratory COA Library
Laboratory report summaries, ordered by issue date when available, otherwise analysis date. Commercial identifiers are redacted from the PDF copies. EULIX inventory matching and laboratory authentication remain pending.
Tesamorelin · 10 mg
Document reference: ELX-COA-02
Laboratory: FREEDOM
COA issued: July 18, 2026
Retatrutide · 10 mg
Document reference: ELX-COA-03
Laboratory: BTLabs
Analysis date: July 7, 2026
COA issued: July 10, 2026
Retatrutide · 20 mg
Document reference: ELX-COA-04
Laboratory: BTLabs
Analysis date: July 7, 2026
COA issued: July 10, 2026
Retatrutide · 30 mg
Document reference: ELX-COA-05
Laboratory: BTLabs
Analysis date: July 7, 2026
COA issued: July 10, 2026
MOTS-c · 20 mg
Document reference: ELX-COA-06
Laboratory: BTLabs
Analysis date: July 7, 2026
COA issued: July 10, 2026
Review pending: the report identifier also appears on a different sample report. Reported potency is 111.3%, above the printed 90–110% range.
View COA PDFCJC-1295 / Ipamorelin · 10 mg (5 + 5 mg)
Document reference: ELX-COA-07
Laboratory: JANOSHIK
Analysis date: July 7, 2026
Retatrutide · 20 mg
Document reference: ELX-COA-08
Laboratory: JANOSHIK
Analysis date: July 7, 2026
KLOW · 80 mg
Document reference: ELX-COA-09
Laboratory: JANOSHIK
Analysis date: June 16, 2026
Tirzepatide · 30 mg
Document reference: ELX-COA-10
Laboratory: JANOSHIK
Analysis date: June 16, 2026